Your session is about to expire
← Back to Search
Hormone + HER2-targeted Therapy for Breast Cancer (ADEPT Trial)
ADEPT Trial Summary
This trial is studying a combination of HER2-directed therapies and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.
ADEPT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowADEPT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ADEPT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had surgery for my current breast cancer.I have a small, ER+ (≥ 10%), HER2-negative tumor in addition to my primary HER2 positive tumor.I am not pregnant, nursing, or if capable of becoming pregnant, I am willing to use contraception.I have had breast cancer before.I am a man not willing to use birth control.Both of my breasts have cancers that qualify for the trial.All my tumors meet the trial's eligibility criteria.You have taken a new medicine for a short time before having surgery.You are currently taking any other experimental drugs to treat breast cancer.I have not received chemotherapy before or after surgery for this breast cancer.I had cancer before, but it meets the trial's specific criteria.I am willing to donate my stored tissue samples for research.I am fully active or can carry out light work.I am willing and able to complete questionnaires in English.I do not have any major health issues that would prevent me from following the study's requirements.My organs and bone marrow are functioning normally.My cancer was advanced but localized when diagnosed.I am 18 years old or older, regardless of my menopausal status.I have had my ovaries removed.My breast cancer is HER2-positive, early stage, and has not spread to lymph nodes or only has tiny spread.I had DCIS on the same side and haven't had hormone therapy.I have had up to 8 weeks of hormone therapy for my cancer.
- Group 1: PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the combined Pertuzumab+TRASTUZUMAB treatment achieved regulatory acceptance?
"Based on the current evidence, we have assigned a safety rating of 2 to Pertuzumab+TRASTUZUMAB as this is a Phase II trial which has provided some data that suggests it is safe but none regarding its efficacy."
To what type of disorder is Pertuzumab+TRASTUZUMAB most frequently prescribed?
"Pertuzumab+TRASTUZUMAB is routinely used to treat inflammatory breast cancer (IBC) and can be prescribed to address several other ailments such as estrogen receptors, malignant neoplasms, or ovarian cancer."
How many individuals are involved in this experiment?
"Affirmative. According to clinicaltrials.gov, this medical experiment is actively searching for participants and was posted on the 11th of January 2021 before being updated as recently as November 14 2022. It seeks 375 people from 18 different sites."
How widespread is this research endeavor throughout the state?
"Potential participants can find a trial location at Dana-Farber Brigham Cancer Center - Foxborough in Foxboro, New york University Langone Hospital - Long Island in Mineola, and Dana-Farber at Milford in Milford. Additionally, there are 15 other sites currently offering this medication to patients."
What evidence exists for the effectiveness of Pertuzumab+TRASTUZUMAB combinatory therapy?
"The combination of Pertuzumab and Trastuzumab was initially researched in 1994 at Queen Mary University of London. As of now, 973 trials have been concluded while 483 are still ongoing; many taking place around Foxboro, Massachusetts."
Are there any openings for volunteers in this research endeavor?
"According to the information posted on clinicaltrials.gov, those interested in participating can do so as this trial is actively recruiting patients. It was initially made available on November 1st 2021 and has been revised most recently on November 14th 2022."
Share this study with friends
Copy Link
Messenger